Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing

Citation for published version:
Generation Scotland 2014, 'Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study', *BMC Medical Genetics*, vol. 15, no. 1, pp. 70. https://doi.org/10.1186/1471-2350-15-70

Digital Object Identifier (DOI):
10.1186/1471-2350-15-70

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
*BMC Medical Genetics*

Publisher Rights Statement:
© 2014 Norsworthy et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study

Penny J Norsworthy, Jana Vandrovcova, Ellen RA Thomas, Archie Campbell, Shona M Kerr, Jennifer Biggs, Laurence Game, Anne K Soutar, Blair H Smith, Anna F Dominiczak, David J Porteous, Andrew D Morris, Generation Scotland and Timothy J Aitman

Abstract

**Background:** Familial hypercholesterolaemia (FH) is a common Mendelian condition which, untreated, results in premature coronary heart disease. An estimated 88% of FH cases are undiagnosed in the UK. We previously validated a method for FH mutation detection in a lipid clinic population using next generation sequencing (NGS), but this did not address the challenge of identifying index cases in primary care where most undiagnosed patients receive healthcare. Here, we evaluate the targeted use of NGS as a potential route to diagnosis of FH in a primary care population subset selected for hypercholesterolaemia.

**Methods:** We used microfluidics-based PCR amplification coupled with NGS and multiplex ligation-dependent probe amplification (MLPA) to detect mutations in LDLR, APOB and PCSK9 in three phenotypic groups within the Generation Scotland: Scottish Family Health Study including 193 individuals with high total cholesterol, 232 with moderately high total cholesterol despite cholesterol-lowering therapy, and 192 normocholesterolaemic controls.

**Results:** Pathogenic mutations were found in 2.1% of hypercholesterolaemic individuals, in 2.2% of subjects on cholesterol-lowering therapy and in 42% of their available first-degree relatives. In addition, variants of uncertain clinical significance (VUCS) were detected in 1.4% of the hypercholesterolaemic and cholesterol-lowering therapy groups. No pathogenic variants or VUCS were detected in controls.

**Conclusions:** We demonstrated that population-based genetic testing using these protocols is able to deliver definitive molecular diagnoses of FH in individuals with high cholesterol or on cholesterol-lowering therapy. The lower cost and labour associated with NGS-based testing may increase the attractiveness of a population-based approach to FH detection compared to genetic testing with conventional sequencing. This could provide one route to increasing the present low percentage of FH cases with a genetic diagnosis.

**Keywords:** Familial hypercholesterolaemia, Total cholesterol, LDLR, Molecular diagnostic testing, Next-generation sequencing, Primary care, Generation Scotland
Background

Familial hypercholesterolaemia (FH, OMIM no.143890) is a common autosomal dominant disorder characterised by raised serum cholesterol, increased arterial deposition of low density lipoprotein (LDL)-cholesterol and high risk of premature coronary heart disease (CHD). Clinical diagnosis is based on the presence of raised total or LDL-cholesterol, tendon xanthomata, corneal arcus, family history and the presence of FH-causing mutations in the LDLR, PCSK9 or APOB genes [1]. The prevalence of FH is estimated to be between 1/200 and 1/500 [2,3], and while most of the excess risk of premature CHD can be averted by cholesterol lowering drugs, currently only 12-25% of cases in the UK, and <1% in the USA are believed to have a molecular diagnosis [3,4].

Genetic testing and family cascade screening has been proposed as the most cost-effective strategy for detecting cases of FH [3,5], and for distinguishing monogenic FH from sporadic or polygenic hypercholesterolaemia [6]. This strategy was adopted in the 2008 UK guidelines from the National Institute for Health and Clinical Excellence (NICE) [7]. However, implementation of these guidelines in England has been limited due to poor availability, low throughput and high costs of traditional genetic testing, fragmented service delivery and lack of investment in identification of index cases.

We previously demonstrated that next generation sequencing (NGS) is suitable for FH mutation detection in patients attending lipid clinics, with similar sensitivity and specificity to conventional capillary sequencing [8]. Moreover, NGS mutation detection is suited to high-throughput testing of large numbers of samples, which is not so readily achievable with standard capillary sequencing platforms. Since the majority of undiagnosed FH patients receive their healthcare outside lipid clinics, we sought to assess the feasibility of targeted sequence-based genetic testing for FH in a primary care-based population subset selected for hypercholesterolaemia.

Methods

DNA samples

The Generation Scotland: Scottish Family Health Study (GS:SFHS) is a repository of anonymised biological samples and accompanying clinical, biochemical and family data from 23,960 Scottish residents [9]. The ability to recruit at least one first-degree relative was a condition for participation in the GS:SFHS, and therefore around two thirds of those taking part are consenting adult relatives of recruits and volunteers.

We selected a subset of GS:SFHS subjects for genetic analysis using criteria designed to enrich the test population for individuals likely to have FH, based on previously reported population total cholesterol data in FH [10,11], and using additional age and body mass index (BMI) thresholds to reduce inclusion of age- and obesity-related cases of hyperlipidaemia (Figure 1). Triglyceride levels were not measured in the Generation Scotland cohort and therefore data for LDL-cholesterol were not available. Subjects were consequently selected for study on the basis of total cholesterol data. In total, 617 unrelated subjects were obtained from the GS:SFHS and passed quality control (QC; see below) for NGS and MLPA: 193 individuals with raised total cholesterol (designated high cholesterol group), 232 individuals with moderately high total cholesterol despite cholesterol-lowering therapy (cholesterol-therapy group) and 192 normocholesterolamic controls. The control group, also from the GS:SFHS study, were selected to be closest to the population specific mean total cholesterol level, and were age, sex and BMI matched to the high cholesterol group (Table 1 and Figure 1). Total cholesterol cut-off thresholds for each study group are defined in Figure 1. Of all study subjects, 84.1% were White Scottish, 8.6% other Caucasians, 2.0% mixed race and other ethnic groups, and 5.3% unknown ethnicity.

Demographic data of the study population is summarised in Table 1. The median age of the cholesterol-therapy group was higher than the high cholesterol and control groups reflecting higher cholesterol-lowering drug prescription rates in older subjects in this primary care population. 40% of these individuals were known to be taking statins, while the remainder were on unspecified cholesterol lowering medication. Study subjects in the cholesterol-therapy group were selected from those with total cholesterol ≥5.5 mmol/l, these being unlikely to have achieved lipid-lowering therapy targets for FH [12]. DNA samples for available first-degree relatives of index cases who tested positive for FH mutations were obtained from the GS:SFHS repository, and were tested by Sanger sequencing for mutations detected in their respective proband relatives. Ethical approval for the GS:SFHS study was obtained from the Tayside Committee on Medical Research Ethics (on behalf of the National Health Service). All patients provided informed consent for the use of their data and samples for medical research.

Mutation detection

The full LDLR coding sequence, all four exons known to harbour FH mutations in PCSK9, and the known mutation hot spot in APOB were amplified using the 48.48 Access Array (Fluidigm, San Francisco, USA) and pooled samples sequenced on a MiSeq sequencer (Illumina, San Diego, USA) as described [8]. Due to the very low likelihood of detecting mutations that could be definitively shown to be pathogenic in the remainder of the PCSK9 and APOB genes, it was considered that inclusion of these regions in the assay would not be informative and these regions were therefore not included in the assay.
In addition, because of the low frequency of known mutations outside coding regions or splice sites, intronic regions outside splice sites were not covered in this assay.

DNA sequences were considered to have passed QC if >90% of all nucleotides were covered at ≥15× and >98% of \textit{LDLR} coding regions were covered at ≥15×. Mean coverage for all DNA samples passing QC across all amplicons was 2023× with a mean of 95.2% of bases covered at least 15×. Although this level of coverage falls below recent recommendations for clinical grade sequencing [13], our group established high sensitivity (98%) and specificity (100%) for this NGS-assay at comparable levels of coverage in a lipid clinic population [8]. Recent advances in MiSeq sequencing protocols and further assay optimisation would, however, allow further development that could lead to levels of coverage that meet present recommendations.

The presence of large insertions/deletions was detected using the MLPA (Multiplex Ligation-dependent Probe Amplification) \textit{LDLR}-P062 kit (MRC-Holland, Amsterdam, The Netherlands) following the manufacturer’s protocol including recommendations for QC.

**Variant analysis**

DNA sequences were mapped to the human GRCh37 reference assembly and variant calls generated and annotated as described [8]. Variants with minor allele frequency reported at greater than 1% in Ensembl [14], and intronic variants outside exon-intron boundaries were considered non-pathogenic and were excluded from further analysis. Remaining variants were compared to an FH locus-specific database [14,15], HGMD professional [16], and annotated \textit{in silico} using Variant Effect Predictor [14] and Mutation

---

**Table 1 Characteristics of Generation Scotland groups studied**

| Group                          | Age (yr) | Sex distribution | BMI       | Total cholesterol (mmol/l) |
|-------------------------------|----------|------------------|-----------|---------------------------|
| High cholesterol (n = 193)    | 44–88    | 41/59            | 26.9 (18.7–47.4) | 8.1 (7.0–12.0) |
| Control (n = 192)             | 45–84    | 42/58            | 26.4 (14.2–44.6) | 5.2 (5.0–5.3) |
| Cholesterol-therapy (n = 232) | 60–88    | 43/57            | 28.1 (18.1–56.6) | 5.9 (5.5–9.5) |

Median data are given for age, BMI and total cholesterol. Ranges are shown in brackets.
Taster [17]. Variants described unequivocally as FH-causing in mutation databases were classified as pathogenic. All remaining known variants were classified as variants of uncertain clinical significance (VUCS) unless published data indicated that these variants are likely benign. Novel missense variants were also classified as VUCS. Novel sequence changes outside coding regions and essential splice sites, and synonymous coding changes were considered likely benign. As only 5’ and 3’ ends of introns were represented in our NGS-assay, intronic variants outside splice sites were not evaluated. All rare variants were verified by conventional Sanger sequencing and the single detected duplication was confirmed by PCR.

Results
Mutation detection
FH-causing mutations were detected in 4 out of 193 (2.1%) subjects in the high-cholesterol group and in 5 out of 232 (2.2%) subjects in the cholesterol-therapy group (Table 2). All nine mutations have been previously reported as pathogenic in FH patients [15,16]. No FH-causing mutations were detected in the 192 subjects in the normocholesterolaemic control group.

Five VUCS were detected in six subjects from the high-cholesterol and cholesterol-therapy groups (Table 2), but none in normocholesterolaemic controls. Three of the five detected variants have been previously reported in FH patients but their pathogenicity is unclear [8,15]. The two missense changes, p.Glu92Lys substitution in PCSK9 and p.Val765Gly in LDLR, have not been reported before and further segregation and functional studies will be needed to clarify the pathogenicity of these variants.

Two additional rare non-synonymous coding sequence variants in LDLR were identified in three study subjects, but their previously reported presence in normocholesterolaemic individuals has led to their classification as benign variants [18]. The p.Arg744Gln variant was found in two cholesterol-treated subjects not known to be related, whose total cholesterol measurements on treatment were 7.7 mmol/l and 9.5 mmol/l. The p.Ala50Ser was found in one control subject (total cholesterol 5.3 mmol/l).

Cascade testing
DNA was available for cascade testing in relatives of six of the index cases identified here as having pathogenic mutations. From a total of twelve available first-degree relatives, five molecular diagnoses of FH were made: one from the two relatives of index case 4, three from the five relatives of index case 8, and one from the single relative of index case 9 (Table 2). In all cases mutations identified in relatives were the same as that of the associated index case. Single first-degree relatives of index cases 2 and 5, and two first-degree relatives from index case 7, were mutation negative. Cholesterol data was available for three of the five new molecular diagnoses: two of these subjects had relatively high cholesterol levels despite being on cholesterol-lowering therapy (5.0 mmol/l and 5.5 mmol/l); the third subject was untreated, with a cholesterol level of 7.7 mmol/l.

Discussion
Sequence-based detection of index cases and family cascade testing offer a possible route to diagnosis of FH in primary care, but this approach has not been evaluated to date. In this study we have used our recently validated NGS-based assay [8] and MLPA to detect FH-causing mutations in a primary care-based population in subjects who, based on readily available clinical data, were considered to have an increased risk of FH compared to the general population. In the sample of GS:SFHS patients tested, we found pathogenic, FH-causing mutations in 2.1% of unrelated high-risk individuals and none in normocholesterolaemic controls. A further five FH cases were identified through cascade testing of first degree relatives of index cases by testing for the identified mutation found in each index case. We also detected VUCS in 1.4% of the high-cholesterol and cholesterol-therapy groups, but none in normocholesterolaemic controls. Further functional and segregation studies will be needed to clarify pathogenicity of these variants. The interpretation of VUCS in NGS projects remains a challenge, although given the present rapid increase in available, clinically relevant sequencing data and the expansion of disease-specific databases, we anticipate that the clinical interpretation of variants currently classified as VUCS is likely to become easier in the coming months and years.

The GS:SFHS is a primary care-based study of subjects aged 35–65 at recruitment, and their consenting adult relatives, phenotyped for a range of biochemical and morphometric parameters including body mass index, total cholesterol and history of medical prescriptions [9]. These clinical details were used to ascertain subjects who would be enriched for FH-causing mutations, but in most cases were not sufficient to apply formal clinical diagnostic criteria for FH (Simon Broome or Dutch Lipid Clinic) [19,20]. No data was collected on clinical phenotypes such as tendon xanthomata, and while some family history information was collected, it did not include sufficient detail (for example age at onset of cardiovascular disease) to apply Simon Broome or Dutch Lipid Clinic criteria. A family history of hypercholesterolaemia could only be established for those with relatives who had been recruited to the study. In subjects from the cholesterol-therapy group, pre-treatment cholesterol measurements were not available. Although preventing clinical diagnostic criteria from being applied, this level of information is analogous to the available data in a previous UK study of FH which used casenote review without genetic testing in
Table 2 Pathogenic FH mutations and variants of uncertain clinical significance (VUCS) found in Generation Scotland subjects

| No. | Age | Sex | Total cholesterol (mmol/l) | Group | Gene | Nucleotide change | Protein change | PolyPhen2 prediction | SIFT prediction | Mutation taster | n   |
|-----|-----|-----|---------------------------|-------|------|-------------------|----------------|----------------------|----------------|----------------|-----|
| **Pathogenic mutations** | | | | | | | | | | | |
| 1  | 51  | F   | 12.0                      | High cholesterol | APOB  | c.10580G > A      | p.Arg3527Gln   | Probably damaging   | Deleterious    | Polymorphism   | 1   |
| 2  | 44  | F   | 8.9                       | LDLR              | LDLR  | c.693C > G        | p.Cys231Trp    | Probably damaging   | Deleterious    | Disease causing | 1   |
| 3  | 36  | M   | 7.0                       | LDLR              | LDLR  | c.268G > A        | p.Asp90Asn     | Probably damaging   | Deleterious    | Disease causing | 1   |
| 4  | 61  | F   | 8.3                       | LDLR              | LDLR  | c.718G > A        | p.Glu240Lys    | Possibly damaging   | Deleterious    | Disease causing | 1   |
| 5  | 56  | M   | 5.9                       | Cholesterol-therapy | APOB  | c.10580G > A      | p.Arg3527Gln   | Probably damaging   | Deleterious    | Polymorphism   | 1   |
| 6  | 57  | M   | 5.7                       | LDLR              | LDLR  | c.326G > A        | p.Cys109Tyr    | Probably damaging   | Deleterious    | Disease causing | 1   |
| 7  | 50  | M   | 5.9                       | LDLR              | LDLR  | c.1133A > C       | p.Gln378Pro    | Probably damaging   | Deleterious    | Polymorphism   | 1   |
| 8  | 71  | F   | 5.5                       | LDLR              | LDLR  | c.232C > T        | p.Arg78Cys     | Probably damaging   | Tolerated      | Disease causing | 1   |
| 9  | 60  | F   | 6.2                       | LDLR              | LDLR  | c.1586-?_1845 + ?dup | Not applicable | Not applicable      | Not applicable | Not applicable | 1   |

(Exon 11 and 12 duplication)

| **VUCS** | | | | | | | | | | | |
| 10 | 32  | F   | 7.7                      | High cholesterol | PCSK9 | c.274G > A       | p.Glu92Lys     | Benign               | Tolerated      | Polymorphism   | 1   |
| 11 | 31  | M   | 8.7                      | LDLR              | LDLR  | c.121T > C       | Not applicable  | Not applicable       | Not applicable | Polymorphism   | 1   |
| 12 | 54  | F   | 8.2                      | LDLR              | LDLR  | c.1816G > T      | p.Ala606Ser    | Possibly damaging    | Tolerated      | Disease causing | 1   |
| 13 | 63  | M   | 5.5                      | Cholesterol-therapy | LDLR  | c.2294T > G      | p.Val765Gly    | Benign               | Tolerated      | Polymorphism   | 2   |
| 14 | 61  | M   | 7.0                      | LDLR              | LDLR  | c.2479G > A      | p.Val827Ile    | Probably damaging    | Deleterious    | Disease causing | 1   |
| 15 | 36  | M   | 6.0                      | LDLR              | LDLR  | c.2479G > A      | p.Val827Ile    | Probably damaging    | Deleterious    | Disease causing | 1   |

n, number of individuals with variant, *All variants had been reported previously apart from c.274G > A and c.2294 T > G which were novel variants, †Not known to be related.
a primary care setting [10]. This highlights the differences in entry criteria between primary care and Lipid Clinic populations, and illustrates the importance of careful selection criteria for this approach to molecular diagnosis in primary care. Of interest, however, was that within our high cholesterol group, a subset of 50 individuals who were aged 40 or under had total cholesterol 7–7.4 mmol/l and therefore do not meet Simon Broome criteria for FH. One of this group was found to have an FH causing mutation (see below).

The mutation detection rate reported here is considerably lower than in Lipid Clinic populations tested according to defined clinical criteria [8,21], but is higher than the detection rate in an unsellected population study in Copenhagen, in which only 20% of those diagnosed clinically as having probable or definite FH (0.73% of the study population) were found by genotyping to have a common FH mutation [22]. The low FH detection rate in comparison to Lipid Clinic populations is most likely a consequence of the limited clinical data such as the absence of information on tendon xanthomata and LDL-cholesterol, as well as the probable inclusion of individuals with polygenic and lifestyle related hypercholesterolaemia which is reportedly of high prevalence in the Scottish compared to the English population [23] which may also have affected our ability to enrich this group for genetic effects. The availability of data on LDL-cholesterol and presence or absence of tendon xanthomata in future study populations, as well as genetic testing in populations with a lower background frequency of cardiovascular disease are likely to allow greater enrichment for patients with FH in those selected for testing, with a corresponding higher FH detection rate.

Treatment targets are more stringent in FH compared to sporadic hypercholesterolaemia owing to the greater vascular risk caused by lifelong high cholesterol levels [12], and therefore it is notable that the number of molecular diagnoses we made in the cholesterol-therapy group was similar to that of the high cholesterol group. Although individuals in the cholesterol-therapy group are receiving lipid-lowering medication, their relatively high cholesterol levels (5.5 – 6.2 mmol/l) suggest suboptimal treatment, which could most likely be addressed by more aggressive lipid-lowering therapy, ideally in a lipid clinic. Molecular diagnosis in these individuals would also permit cascade testing of their relatives. Consistent with the experience from the Dutch cascade screening programme [3,24], these data illustrate the advantages of identifying FH in primary care by genetic testing in order to distinguish FH patients definitively from those with other types of hypercholesterolaemia. Making use of NGS-based techniques to identify FH cases in primary care also provides a feasible alternative to reliance on lipid clinics in countries such as England and the USA where genetic testing for FH is not generally carried out and overall diagnostic rates remain low.

The selection criteria we employed here may not detect all mutation positive FH cases in primary care. For example, Index Case 3 (Table 1; TC = 7.0 mmol/l) was on the lower cholesterol threshold for inclusion in our study. In addition, since only 13% of patients in the GSS:SFHS on cholesterol-lowering therapy had total cholesterol ≥5.5 mmol/l, further testing of subjects on cholesterol-lowering therapies but with cholesterol <5.5 mmol/l would be likely to make further molecular diagnoses of FH and these would be a source of additional cases through family cascade testing.

Conclusions

To our knowledge, this is the first study of FH based on DNA sequencing in a primary care population. Previous studies to detect FH in primary care populations have been based on clinical criteria alone [10,25], or genotyping for common mutations [22]. We have evaluated the targeted use of high-throughput NGS-based methods for detection of FH cases in primary care, and demonstrated that population-based genetic testing using these protocols is able to deliver definitive molecular diagnoses of FH in high-risk individuals. Because detection of FH cases in primary care would require testing of much larger numbers of subjects than detection of cases in secondary care, the lower cost and labour associated with NGS-based testing [8,26,27] could increase the attractiveness of a population-based approach to FH detection compared to genetic testing with conventional sequencing. Coupled with genetic testing in lipid clinics, selective NGS-based population screening with family cascade testing could therefore be one route to increasing the present low percentage of FH cases with a genetic diagnosis. Detailed studies should now be undertaken to establish the feasibility and cost-effectiveness of this approach.

Abbreviations

APOB: Apolipoprotein B; BMI: Body mass index; CHD: Coronary heart disease; FH: Familial hypercholesterolaemia; GSS:SFHS: Generation Scotland: Scottish family health study; HGMD: Human gene mutation database; LDL: Low density lipoprotein; LDLR: Low density lipoprotein receptor; MLPA: Multiplex ligation-dependent probe amplification; NGS: Next generation sequencing; NICE: National institute for health and clinical excellence; PCSK9: Proprotein convertase subtilisin/kexin type 9; QC: Quality control; TC: Total cholesterol; VUCS: Variant of uncertain clinical significance.

Competing interests

TJA and JV have a UK patent application pending on the NGS assay used in this report but have no plans to develop the patent. The remaining authors declare that they have no competing interests.

Authors’ contributions

PJN carried out NGS assays, MLPA and compiled the clinical data. JV designed the NGS assay, oversaw data generation and analysed the NGS data. ERAT, JV, AKS, AC, SMK and TJA designed the selection criteria in Figure 1 and collated clinical information. AC and SMK supplied DNA samples and clinical data from the GSS:SFHS resource. JB validated NGS data by capillary sequencing. LG oversaw generation of NGS MiSeq data. AKS participated in study design and preparation of the manuscript. BrS, AD, DP and AM conceived and oversee the

Norworthy et al. BMC Medical Genetics 2014, 15:70
http://www.biomedcentral.com/1471-2350/15/70
GGSFHS. TJA conceived and oversaw the study. PJN, JV and TJA co-wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Generation Scotland has received core funding from the Chief Scientist Office of the Scottish Government Health Directorates C2D/16/6 and the Scottish Funding Council HR03006. We also acknowledge funding from the MRC Clinical Sciences Centre and the British Heart Foundation to TJA, from a Wellcome Trust Clinical Training Fellowship to ERAT, and from the NIHR-funded Imperial Biomedical Research Centre to TJA. We are grateful to all the families who took part in the GGSFH, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses.

Author details

1MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, London, UK. 2Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, UK. 3Medical Research Institute, University of Dundee, Dundee, UK. 4College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. 5Generation Scotland, A Collaboration between the University Medical Schools and NHS in Aberdeen, Dundee, Edinburgh and Glasgow, UK.

Received: 4 March 2014 Accepted: 28 May 2014

References

1. van der Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, Huijgen R, Fouchier SW, Wijburg FA, Kastelen JJ, Wiegman A: Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011, 123(1):1161-1173.
2. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG, Kasperaviciute D, Biggs J, Game L, Mueller M, Soutar AK, Aitman TJ: Hypercholesterolaemia: summary of NICE guidance. BMJ 2014 (1):938-941.
3. Nordestgaard BG, Chapman MJ, Humphries SE, Sindberg HM, Masana L, Descamps OS, Wiklund O, Hegerle RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Pathoo KG, Kees Hovingh G, Kovaren PT, Boleieu C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pakuapanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, for the European Atherosclerosis Society Consensus P: Familial hypercholesterolaemia is undiagnosed and undertreated in the general population: guidance to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2012, 33(4):347-349.
4. National Clinical Audit of the Management of Familial Hypercholesterolaemia 2010: Full Report. [http://www.rcplondon.ac.uk/resources/audits/FH]
5. Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE: Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011, 97(14):1175-1181.
6. Talmud PJ, Shah S, Whittal R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, Neely RD, Fairgrieve S, Nair D, Barbir M, Jones LS, Egan S, Everalde R, Lolin Y, Hughes E, Cooper JA, Hadfield SG, Norbury G, Humphries SE: Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010, 77(6):572-580.
7. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG: Familial hypercholesterolaemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012, 97(11):3956-3964.
8. Roth GA, Fihn SD, Mokdad AH, Akeplakom H, Wasegawa T, Lim SS: High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ 2011, 89(2):92-101.
9. Huijgen R, Hutten BA, Defesche JC, Vissers MN: Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolaemia. Hum Mutat 2010, 31(6):752-760.
10. Gray J, Jayeola A, Whiting M, Modell M, Wierzbicki AS: Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart 2008, 94(7):754-758.
11. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PH: Diagnosing heterozygous familial hypercholesterolaemia using new practical criteria validated by molecular genetics. Ann Cardiol 1995, 39(2):171-176.
12. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008, 29(21):2625-2633.
13. Rehm HL, Balle SJ, Bayrak-Toydemir P, Berg JS, Brown MK, Deignan JL, Friez MJ, Funkie BH, Hargie MR, Lyon E, Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee: ACMG clinical laboratory standards for next-generation sequencing. Genet Med 2013, 15(9):733-747.
14. Flicek P, Amode MR, Barrell D, Brail K, Bills K, Brent C, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Grön CG, Gordon L, Houlter T, Hunt S, Johnson N, Kuivenhoven JA, Kwan AH, Khan J, Lawrence C, Li K, Drenos F, Karpe F, Neil HA, Descamps OS, Langenberg C, Lench N, Mager D, Melling P, Mikkelsen DT, Nekrutenko A, Ng PC, Norgregor P, Pagnetti M, Pritchard B, Pritchard J, Raitt HS, et al: Ensembl 2014. Nucleic Acids Res 2014, 42(D1):749-755.
15. Leigh SE, Foster AH, Whitall RA, Hubbard CS, Humphries SE: Update and analysis of the University of College London low density lipoprotein receptor familial hypercholesterolaemia database. Ann Hum Genet 2008, 72(Pt 4):485-498.
16. Stenson PD, Mort M, Ball EV, Howard L, Phillips AD, Thomas NS, Cooper DN: The Human Gene Mutation Database 2008 update. Genome Med 2009, 1(11):13.
17. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nature Methods 2010, 7:575-576.
18. Huijgen R, Kint J, Fouchier SW, Defesche JC, Hutten BA, Kastelen JJ, Vissers MN: Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolaemia. Hum Mutat 2010, 31(6):752-760.
19. Scientific Steering Committee on behalf of the Simon Broome Register Group: Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991, 303(6807):893-896.
20. Defesche J: Familial Hypercholesterolemia: In Lipid and Vascular Disease. Edited by Betteridge DJ: London: Martin Dunztd Ltd; 2000:65-700.
21. Taylor A, Wang D, Patel K, Whittal R, Wood G, Farry M, Neely RD, Fairgrieve S, Nair D, Barbir M, Jones LS, Egan S, Everalde R, Lolin Y, Hughes E, Cooper JA, Hadfield SG, Norbury G, Humphries SE: Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010, 77(6):572-580.
22. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG: Familial hypercholesterolaemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012, 97(11):3956-3964.
23. Roth GA, Fihn SD, Mokdad AH, Akeplakom H, Wasegawa T, Lim SS: High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ 2011, 89(2):92-101.
24. Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelen JJ. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolaemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012, 5(3):354-359.
25. Neil HA, Hammond T, Huxley BN, Matthews DR, Humphries SE: Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000, 321(7254):148.
26. Lepri FR, Scavelli R, Digilio MC, Gnazzo M, Grotta S, Dentici ML, Pisaneschi E, Sireto P, Cappolini R, Baban A, Russo S, Franchin T, Angioni A, Dallapiccola B: Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet 2014, 15(1):14.
27. Ware JS, John S, Roberts AM, Buchan R, Gong S, Peters NS, Robinson DO, Lucassen A, Behr ER, Cook SA: Next generation diagnostics in inherited arrhythmia syndromes: a comparison of two approaches. J Cardiovasc Transl Res 2013, 6(1):94-103.

Norsworthy et al. BMC Medical Genetics 2014, 15:70
http://www.biomedcentral.com/1471-2350/15/70

Page 7 of 7